NATCO Pharma Limited (NATCOPHARM)
Valuation Rating
Score: 44/100
Valuation Overview
| P/E Ratio | 11.624171 |
| P/B Ratio | 3.1639273 |
| Dividend Yield | 0.45999999999999996% |
| Current Price | ₹1262.85 |
| DCF Value | ₹1034.3184171990138 |
| Upside Potential | N/A% |
Intrinsic Values
| Current Price | ₹1262.85 |
| DCF Value | ₹1034.3184171990138 |
| Graham Value | ₹3432.490870190697 |
| DDM Value | ₹273.1973168470692 |
| Earnings Value | ₹1267.1715363722185 |
| Average Value | ₹1278.5536003176571 |
Growth Confidence
| Revenue Growth | 0% |
| Earnings Growth | 0% |
| Revenue Confidence | 0% |
| Earnings Confidence | 0% |
| Margin Confidence | 0% |
| Overall Growth Confidence | 0% |
Growth Metrics
| EPS Growth | 83.5% |
| Revenue Growth | 32.9% |
| Market Cap | ₹22625.22 Cr |
Valuation Analysis Score: 44/100
Undervaluation Score: 44/100
Valuation Score: 20/30
Growth Score: 4/30
Intrinsic Value Score: 20/40
Growth Score: 4/30
Intrinsic Value Score: 20/40
Key Analysis Points:
- Excellent P/E ratio below 15
- Excellent operating margins above 20%
- Moderate growth confidence score above 40%
- Significant discount to Graham Value
- Slightly undervalued across multiple valuation methods
Recommendation
Hold - Stock is fairly valued with moderate metrics
Detailed Metrics
Current Price: ₹1,262.85
Operating Margins: 55.3%
Revenue Growth: 0.0%
Earnings Growth: 0.0%
Growth Confidence: 58.1%
Risk Assessment Guide
- Score 80-100: Significantly undervalued with strong fundamentals
- Score 60-79: Moderately undervalued with good potential
- Score 40-59: Fairly valued with balanced metrics
- Score Below 40: Potentially overvalued, exercise caution
Last Updated: 2025-01-23 06:46:34